| 标题 | 发表场所 | 类型 | 时间 |
|---|---|---|---|
| Denifanstat for moderate‐to‐severe acne: A Phase 2, randomized, double‐blind, placebo‐controlled trial | 欧洲皮肤病学和性病学会杂志 | 论文 | 11/2025 |
| First-in-Class FASN Inhibitor Denifanstat Achieved All Endpoints in the Treatment of Acne Vulgaris: Results from a Phase Ⅲ Randomised Placebo Controlled Trial | 2025年欧洲皮肤病与性病学会（EADV）年会 | 口头报告 | 9/2025 |
| First FASN inhibitor ASC40 to treat acne vulgaris patients: final results from a Phase 2 trial | 2024年美国皮肤病学会（AAD）年会 | 海报 | 3/2024 |
| ASC40， an oral once-daily fatty acid synthase (FASN) inhibitor, in patients with acne vulgaris: topline results from a phase 2 randomized, double-blind, placebo-controlled, multicenter trial | 2023年欧洲皮肤病与性病学会（EADV）大会 | 海报 | 10/2023 |
© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号
浙ICP备11050387号-1
